Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
- Is Your Supply Chain Ready For The End Of Class VI?
- Demonstrating Gene Therapy Potency: A Strategic Road Map
- Why In Vivo Innovation, Regulatory Convergence Will Help Shape CGT's Next Chapter
- When Lyophilization Fails At Scale, First Scrutinize Your Formulation
- The 5 Shifts That Could Remake Lyophilization By 2040
- Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026
- Your 7 Decisions To Make Before MES Configuration
- Complete Response Letters For CGTs Share This Common Theme
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Automated DNA Clean-Up Using Magnetic Bead-Based Methods
Discover how to improve DNA clean‑up through a precise magnetic bead–based workflow, as well as how optimized liquid handling enhances yield, purity, and reproducibility for higher confidence in results.
-
Enhancing mAb Production: Advanced Downstream Purification Strategies
Explore how process optimization can address downstream mAb manufacturing bottlenecks, reduce labor and consumable costs, and support more efficient production without compromising performance.
-
End-To-End Process Scalability Of HEK 293 Media For High Titer AAV Production
Explore how controlled bioreactor environments enable optimization of critical process parameters and support robust, scalable AAV production from development through manufacturing.
-
Accelerating Technology Transfer Of A Drug Product
See how structured testing can reduce transfer risk, confirm scalability and reuse strategies, as well as how to improve process robustness and deliver meaningful savings on chemicals and consumables.
-
Revolutionizing Lentiviral Vector Manufacturing For In Vivo, Ex Vivo CAR-T Therapies
Discover how scalable, cost-effective, and high-quality lentiviral vector manufacturing can accelerate both ex vivo and emerging in vivo CAR-T therapies.
-
New Robot-Compatible Sterile Connectors Enhance Cell Therapy Manufacturing
Discover how automating sterile fluid transfers removes human contamination risks, solves operator shortages, and reduces cell therapy manufacturing costs by up to 74%.
-
Impact Of Media Selection
To highlight the importance of media selection, a study was conducted assessing the effect of three commercially available cGMP grade medias and their influence on T-cell phenotype.
-
Evaluating Clone Performance And Cell-Specific Productivity
See how continuous process monitoring and automated at-line analytics support confident CHO clone ranking, consistent cultivation, and scale-up by connecting pH, viable cell density, and more.
-
Scalability And Reproducibility Of The AAV9 Capture Step
Scaling gene therapies beyond rare diseases demands innovation. Discover a chromatography system that boosts efficiency, protects product integrity, and overcomes viral vector manufacturing challenges.
-
Automated Testing For Compound Toxicity Effects
Explore how anti-cancer drugs' toxic effects on intestinal cells limit dosages as well as how 3D organoids and assay automation can enhance drug development by improving testing processes.
NEWSLETTER ARCHIVE
- 10.28.26 -- Accelerating Advanced Therapies: From Development To Manufacturing
- 10.28.26 -- The Manufacturing Reality Behind Advanced Therapy Commercial Scale
- 10.28.26 -- Building More Scalable MSC Processes
- 10.28.26 -- Inside The Pursuit Of A Functional Cure For Type 1 Diabetes
- 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You
- Why In Vivo Innovation, Regulatory Convergence Will Help Shape CGT's Next Chapter
- Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026
- What LSPA's Life Sciences Future Says About The Road Ahead For CGT
- Inside Scaling Next-Gen MSCs Without Scaling Risk
- Inside Kyverna's Autoimmune CAR T Platform Beyond SPS
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts
More Editorial Collections

